Neal D. Shore, MD, discusses how results from the phase 2 ODENZA trial presented at the 2021 ASCO Annual Meeting can help inform multidisciplinary care in patients with advanced prostate cancer. ODENZA is a prospective, randomized, open-label, multicenter, crossover trial that assessed patient preference between darolutamide (Nubeqa) and enzalutamide (Xtandi) in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
The study results showed a numerical, but not statistically significant difference in patient preference favoring darolutamide, with fatigue as a key factor contributing to this preference. The fatigue rates were 36% versus 21% in the enzalutamide versus darolutamide arms, respectively. In the video, Shore discusses the importance of researching and understanding toxicity differences in drugs of the same therapeutic class in order to optimally deliver personalized, multidisciplinary care. Shore is medical director of the Carolina Urologic Research Center.